4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Duality Biotherapeutics, Inc. (9606) operates in the Biotechnology industry and is headquartered in Shanghai, China with about 231 employees. Its market capitalization is roughly CNY 18 billion. In the fiscal year ended 2025-12-31, 9606 reported CNY 1.9B in revenue and (CNY 2.6B) in net income.
Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | CNY 1.9B | CNY 1.9B | CNY 1.8B | CNY 2M |
| Gross Profit | CNY 589M | CNY 785M | CNY 1.4B | CNY 2M |
| Operating Income (EBIT) | (CNY 455M) | (CNY 203M) | CNY 741M | (CNY 370M) |
| Net Income | (CNY 2.6B) | (CNY 1.1B) | (CNY 358M) | (CNY 387M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2024-12-31 |
|---|---|
| Total Revenue | CNY 479M |
| Gross Profit | CNY 125M |
| Operating Income (EBIT) | (CNY 133M) |
| Net Income | (CNY 484M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | CNY 3.9B | CNY 2.1B | CNY 1.5B | CNY 464M |
| Total Liabilities | CNY 1.5B | CNY 4.1B | CNY 2.6B | CNY 1.2B |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 9606 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms